Related references
Note: Only part of the references are listed.Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study
Dominik R. Berthold et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data
Karim Fizazi et al.
LANCET ONCOLOGY (2007)
Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer
Andrew J. Armstrong et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Randomized phase II study of docetaxel plus estramustine and single-agent docetaxel in patients with metastatic hormone-refractory prostate cancer
J.-C. Eymard et al.
ANNALS OF ONCOLOGY (2007)
Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16
DP Petrylak et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2006)
Cytochrome P4502C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity
L Bodin et al.
BLOOD (2005)
Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer
S Oudard et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Activity of docetaxel with or without estramustine phosphate versus mitoxantrone in androgen dependent and independent human prostate cancer xenografts
S Oudard et al.
JOURNAL OF UROLOGY (2003)
Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma
VJ Sinibaldi et al.
CANCER (2002)
Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: A final report of CALGB 9780
DM Savarese et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Dexamethasone does not significantly contribute to the response rate of docetaxel and estramustine in androgen independent prostate cancer
AL Weitzman et al.
JOURNAL OF UROLOGY (2000)
Share Paper
